Sanofi’s shares dipped early Thursday after its atopic dermatitis drug fell short of Wall Street’s expectations in a late-stage trial.
The drugmaker’s anti-OX40L antibody, called amlitelimab, improved “skin clearance and disease severity” versus placebo at ...
↧